Oncoclinicas do Brasil (ONCO3) - Net Assets
Based on the latest financial reports, Oncoclinicas do Brasil (ONCO3) has net assets worth R$1.20 Billion BRL (≈ $235.17 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$8.22 Billion ≈ $1.61 Billion USD) and total liabilities (R$7.02 Billion ≈ $1.38 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore Oncoclinicas do Brasil (ONCO3) cash flow conversion to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$1.20 Billion |
| % of Total Assets | 14.58% |
| Annual Growth Rate | 47.18% |
| 5-Year Change | 396.56% |
| 10-Year Change | 1626.85% |
| Growth Volatility | 219.58 |
Oncoclinicas do Brasil - Net Assets Trend (2013–2024)
This chart illustrates how Oncoclinicas do Brasil's net assets have evolved over time, based on quarterly financial data. Also explore ONCO3 total asset value for the complete picture of this company's asset base.
Annual Net Assets for Oncoclinicas do Brasil (2013–2024)
The table below shows the annual net assets of Oncoclinicas do Brasil from 2013 to 2024. For live valuation and market cap data, see market value of Oncoclinicas do Brasil.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | R$3.38 Billion ≈ $663.69 Million |
+26.24% |
| 2023-12-31 | R$2.68 Billion ≈ $525.74 Million |
+1.78% |
| 2022-12-31 | R$2.63 Billion ≈ $516.54 Million |
+14.21% |
| 2021-12-31 | R$2.30 Billion ≈ $452.27 Million |
+238.38% |
| 2020-12-31 | R$681.17 Million ≈ $133.66 Million |
+3.78% |
| 2019-12-31 | R$656.37 Million ≈ $128.79 Million |
+39.62% |
| 2018-12-31 | R$470.12 Million ≈ $92.25 Million |
+102.26% |
| 2017-12-31 | R$232.44 Million ≈ $45.61 Million |
-4.96% |
| 2016-12-31 | R$244.56 Million ≈ $47.99 Million |
+24.85% |
| 2015-12-31 | R$195.87 Million ≈ $38.43 Million |
+760.41% |
| 2014-12-31 | R$22.77 Million ≈ $4.47 Million |
-52.73% |
| 2013-12-31 | R$48.16 Million ≈ $9.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Oncoclinicas do Brasil's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15398.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | R$3.15 Billion | 100.02% |
| Other Comprehensive Income | R$804.86 Million | 25.58% |
| Total Equity | R$3.15 Billion | 100.00% |
Oncoclinicas do Brasil Competitors by Market Cap
The table below lists competitors of Oncoclinicas do Brasil ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Arvind SmartSpaces Limited
NSE:ARVSMART
|
$301.71 Million |
|
Humasis Co. Ltd
KQ:205470
|
$301.75 Million |
|
WITHSECURE
HE:WITH
|
$301.75 Million |
|
CyberTAN Technology Inc
TW:3062
|
$301.84 Million |
|
Goodrx Holdings Inc
NASDAQ:GDRX
|
$301.64 Million |
|
Korea Environment Technology Co. LTD
KQ:029960
|
$301.63 Million |
|
Bus Online Co Ltd
SHE:002188
|
$301.55 Million |
|
Cybin Inc
NEO:CYBN
|
$301.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncoclinicas do Brasil's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,301,226,000 to 3,146,350,000, a change of 845,124,000 (36.7%).
- Net loss of 646,190,000 reduced equity.
- Dividend payments of 11,656,000 reduced retained earnings.
- Share repurchases of 1,500,000,000 reduced equity.
- New share issuances of 1,500,000,000 increased equity.
- Other comprehensive income increased equity by 789,771,000.
- Other factors increased equity by 713,199,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$-646.19 Million | -20.54% |
| Dividends Paid | R$11.66 Million | -0.37% |
| Share Repurchases | R$1.50 Billion | -47.67% |
| Share Issuances | R$1.50 Billion | +47.67% |
| Other Comprehensive Income | R$789.77 Million | +25.1% |
| Other Changes | R$713.20 Million | +22.67% |
| Total Change | R$- | 36.72% |
Book Value vs Market Value Analysis
This analysis compares Oncoclinicas do Brasil's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.34x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.99x to 0.34x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | R$0.59 | R$1.75 | x |
| 2014-12-31 | R$-0.46 | R$1.75 | x |
| 2015-12-31 | R$0.90 | R$1.75 | x |
| 2016-12-31 | R$0.86 | R$1.75 | x |
| 2017-12-31 | R$0.62 | R$1.75 | x |
| 2018-12-31 | R$1.07 | R$1.75 | x |
| 2019-12-31 | R$1.39 | R$1.75 | x |
| 2020-12-31 | R$1.00 | R$1.75 | x |
| 2021-12-31 | R$3.90 | R$1.75 | x |
| 2022-12-31 | R$3.98 | R$1.75 | x |
| 2023-12-31 | R$4.30 | R$1.75 | x |
| 2024-12-31 | R$5.10 | R$1.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncoclinicas do Brasil utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10.38%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 3.56x
- Recent ROE (-20.54%) is below the historical average (6.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 161.27% | 7.62% | 0.84x | 25.20x | R$19.23 Million |
| 2014 | 0.00% | -6.17% | 1.00x | 0.00x | R$-21.17 Million |
| 2015 | -15.97% | -5.41% | 0.88x | 3.37x | R$-40.28 Million |
| 2016 | -13.05% | -4.26% | 0.96x | 3.19x | R$-44.79 Million |
| 2017 | 1.74% | 0.40% | 1.01x | 4.34x | R$-14.96 Million |
| 2018 | -4.46% | -1.63% | 0.78x | 3.52x | R$-55.39 Million |
| 2019 | -3.67% | -1.21% | 0.80x | 3.79x | R$-76.09 Million |
| 2020 | -39.25% | -7.75% | 0.60x | 8.45x | R$-197.86 Million |
| 2021 | -2.53% | -1.74% | 0.45x | 3.25x | R$-232.30 Million |
| 2022 | 2.18% | 1.13% | 0.50x | 3.88x | R$-165.52 Million |
| 2023 | 9.72% | 4.07% | 0.60x | 3.99x | R$-6.50 Million |
| 2024 | -20.54% | -10.38% | 0.56x | 3.56x | R$-960.83 Million |
Industry Comparison
This section compares Oncoclinicas do Brasil's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $2,758,787,000
- Average return on equity (ROE) among peers: 12.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncoclinicas do Brasil (ONCO3) | R$1.20 Billion | 161.27% | 5.86x | $301.69 Million |
| Hospital Mater Dei S.A (MATD3) | $1.62 Billion | 6.40% | 2.05x | $333.46 Million |
| Rede D'Or São Luiz S.A. (RDOR3) | $3.90 Billion | 18.58% | 1.61x | $14.89 Billion |
About Oncoclinicas do Brasil
Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America. The company offers treatment services, including radiotherapy, hormone therapy, immunotherapy, port-a-cath, palliative care, target therapy, breast cancer hormone therapy, bone marrow transplant, non-oncological infusions, ch… Read more